PGL 0.00% $3.92 prospa group limited.

PGL & Long Suffering Drinkers

  1. 13,465 Posts.
    lightbulb Created with Sketch. 6
    Great news for all concerned & little buyer interest.

    Company Announcements All Ords:

    Clinical Trial Approved for PI-166 - Liver Cancer Therapy

    PROGEN INDUSTRIES LIMITED. 2002-10-29 ASX-SIGNAL-G

    HOMEX - Brisbane

    +++++++++++++++++++++++++
    Please find attached the Company announcement that Progen has
    received hospital ethics committee approval for its new cancer
    therapy PI-166 to be investigated in a Phase I liver cancer trial.
    The trial will be conducted at the St George Hospital in Sydney,
    Australia.

    M McColl
    COMPANY SECRETARY.


    PROGEN RECEIVES APPROVAL FOR HUMAN CLINICAL TRIAL OF POTENTIAL LIVER
    CANCER THERAPY

    Progen Industries Limited (NASDAQ: PGLAF) (ASX: PGL) has received
    hospital ethics committee approval for its new cancer therapy PI-166
    to be investigated in a Phase I liver cancer trial.

    The trial will be conducted at the St George Hospital in Sydney,
    Australia. Professor David Morris of the University of New South
    Wales Department of Surgery will be the chief investigator.

    The primary objective of this Phase I trial will be to investigate
    the safety and tolerability of PI-166 in patients with advanced liver
    cancer (unresectable primary hepatocellular carcinoma).

    "We are very excited to have obtained approval to commence this trial
    just after signing the licensing agreement for PI-166 with Unisearch
    in September. A lot of combined effort has been required to achieve
    this outcome, and this is a positive sign of a strong emerging
    relationship between Progen and our collaborators at UNSW and
    Unisearch," said Progen's Managing Director Lewis Lee.

    PI-166 is a small organic compound with specific avidity to liver
    cancer cells that has shown promising results in animal models of
    liver cancer. "PI-166 complements our lead cancer drug PI-88 which is
    currently in multiple trials in patients with multiple myeloma and
    advanced cancers. It adds significant breadth to our drug development
    capability," he added.

    ABOUT HEPATOCELLULAR CARCINOMA (LIVER CANCER]

    Over 400,000 new cases of primary liver cancer are diagnosed
    worldwide each year and existing treatment options are of limited
    benefit to most patients. Many tumours are inoperable by the time
    they are diagnosed and furthermore, they are usually resistant to
    available drug treatments.

    Liver cancer is often a long-term consequence of chronic liver
    disease from hepatitis B and C infection or alcohol abuse. It is the
    fifth most common cancer in the world due to the high incidence of
    hepatitis in Asia, but is a leading cause of cancer morbidity and
    death in countries most afflicted. Australia has seen a 50% increase
    in mortality in the last 10 years.

    Despite intense research in this area little improvement has been
    gained in treatment outcomes, and the survival statistics reveal a
    huge unmet clinical need.

    The estimated market potential for an affordable treatment for
    primary liver cancer is US$500 million.

    PROGEN ENQUIRIES:
    Lewis Lee
    MANAGING DIRECTOR,
    Progen Industries Limited
    Tel: ++61 7 3273 9100

    PATIENT ENQUIRY LINE
    Email: [email protected]
    Tel: ++ 61(0)417 436 548 (Australia)

    MEDIA ENQUIRIES;
    Australia:
    Kate Mazoudier, Monsoon Communications
    Tel ++ 61 403 497 424

    US:
    Stephen Anderson, Six Sigma Group
    Tel: ++ 1-415-776-6499


 
watchlist Created with Sketch. Add PGL (ASX) to my watchlist
(20min delay)
Last
$3.92
Change
0.000(0.00%)
Mkt cap ! $632.4M
Open High Low Value Volume
$3.92 $3.92 $3.87 $85.29K 21.91K

Buyers (Bids)

No. Vol. Price($)
3 7303 $3.85
 

Sellers (Offers)

Price($) Vol. No.
$3.92 5985 1
View Market Depth
Last trade - 16.10pm 13/11/2019 (20 minute delay) ?
(live)
Last
$3.90
  Change
0.000 ( 0.00 %)
Open High Low Volume
$3.90 $3.90 $3.90 22000
Last updated 11.39am 13/11/2019 (live) ?
PGL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.